A prospective study of age trends of high-risk human papillomavirus infection in rural China

BMC Infectious Diseases

You-Lin Qiao³  Xun Zhang³  Wen Chen³  Jing Li³  Pooja Bansil²  Feng Chen³  Jose Jeronimo²  Fang-Hui Zhao³  Philip E Castle¹  Le-Ni Kang³ 

[1] Global Cancer Initiative, 100 Radcliff Drive, Chestertown, MD, 21620, USA;PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA;Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Lane, Beijing, 100021, China

关键词: Cohort effect;    Risk factor;    Age;    Infection;    Human papillomavirus;   

Others  :  1134540
DOI  :  10.1186/1471-2334-14-96

 received in 2013-11-09, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

In China, high-risk human papillomavirus (HR-HPV) prevalence is unexpectedly high in older women, but the possible reasons have not been well studied yet. This study investigated the age trends of HR-HPV infection in a prospective study.

Methods

A total of 7397 women aged 25-65 years without cervical precancer or cancer were evaluated during 2010-2011 with a stratified sample of 2791 women re-evaluated after one year. Test results for careHPV and careHPV16/18/45 were used to describe the HR-HPV prevalence, incidence and clearance. Risk factors associated with HR-HPV infections were explored using a logistic regression model.

Results

The overall HR-HPV prevalence was 13.1% at baseline, with a peak of 19.3% in women aged 55-59 years. The prevalence of HR-HPV (p for trends < 0.001), HPV16/18/45 (p for trends = 0.002), and HR-HPV other than HPV16/18/45 (p for trends = 0.002) generally increased with increasing age. Number of infections that cleared was generally greater than number of incident infections within age groups. One-year clearance rate decreased with increasing age (p for trends < 0.001), however, incidence rate was unrelated to age (p for trends = 0.159). Risk factors that associated with HR-HPV infection differed between younger and older women.

Conclusions

The greater HR-HPV prevalence in older versus younger women in rural China may be explained by a cohort effect, higher than expected incidence, and/or poorer clearance at older age.

【 授权许可】

   
2014 Kang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
• [2]Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, et al.: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
• [3]Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, et al.: Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006, 119:2677-2684.
• [4]Ferreccio C, Prado RB, Luzoro AV, Ampuero SL, Snijders PJ, Meijer CJ, Vaccarella SV, Jara AT, Puschel KI, Robles SC, et al.: Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 2004, 13:2271-2276.
• [5]Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, et al.: Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005, 191:1796-1807.
• [6]Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, et al.: Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004, 91:942-953.
• [7]Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T: Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008, 123:1864-1870.
• [8]Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, Huang RD, Sun LX, Meijer CJ, Qiao YL, et al.: Human papillomavirus infection in Shanxi Province, People’s Republic of China: a population-based study. Br J Cancer 2006, 95:96-101.
• [9]Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Qiao YL, et al.: Human papillomavirus infection in Shenyang City, People’s Republic of China: a population-based study. Br J Cancer 2006, 95:1593-1597.
• [10]Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, et al.: Human papillomavirus infection in women in Shenzhen City, People’s Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer 2007, 121:1306-1311.
• [11]Liu SS, Chan KY, Leung RC, Chan KK, Tam KF, Luk MH, Lo SS, Fong DY, Cheung AN, Lin ZQ, et al.: Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One 2011, 6:e19244.
• [12]Yu XW, Zhang XW, Wang L, Li F, Xu J: Status of human papillomavirus infection in the rural female population in Northwestern China: an observational study. J Low Genit Tract Dis 2013, 17:17-22.
• [13]Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, Wu RF, Li CQ, Wei LH, Xu AD, et al.: Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer 2012, 131:2929-2938.
• [14]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
• [15]Boulet GA, Horvath CA, Berghmans S, Bogers J: Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev 2008, 17:810-817.
• [16]Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
• [17]Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, ALTS Group: A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007, 195:1582-1589.
• [18]Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS: Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:123-137.
• [19]Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, et al.: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012, 137:516-542.
• [20]Gage JC, Ajenifuja KO, Wentzensen N, Adepiti AC, Stoler M, Eder PS, Bell L, Shrestha N, Eklund C, Reilly M, et al.: Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer 2012, 131:2903-2909.
• [21]Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, et al.: A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008, 9:929-936.
• [22]Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, et al.: An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila) 2013, 6:938-948.
• [23]Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL, et al.: Colposcopy directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004, 191:430-434.
• [24]Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M: A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol biomarkers Prev 2003, 12:477-484.
• [25]Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M: Age standardization of rates: a new WHO standard. Series: No . 31. Geneva: World Health Organization Press; 2001:10. [www.who.int/healthinfo/paper31.pdf webcite]
• [26]Moodley JR, Constant D, Hoffman M, Salimo A, Allan B, Rybicki E, Hitzeroth I, Williamson AL, et al.: Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study. BMC Cancer 2009, 9:275. BioMed Central Full Text
• [27]Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras C, Silva S, González P, Bratti MC, et al.: Comparison of the SPF10-LiPA system to the hybrid capture 2 assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol 2007, 45:1447-1454.
• [28]Smith JS, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43(4 Suppl):S5-S25.
• [29]Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, Woodman CB: High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002, 109:96-98.
• [30]Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA: Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157:218-226.
• [31]Rodriguez AC, Burk R, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillen D, Alfaro M, Viscidi R, et al.: The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life. Sex Transm Dis 2007, 34:494-502.
• [32]Moscicki AB: Management of adolescents who have abnormal cytology and histology. Obstet Gynecol Clin North Am 2008, 35:633-643.
• [33]Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD: A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005, 191:1808-1816.
• [34]Wang C: History of the Chinese family planning progrom: 1970-2010. Contraception 2012, 85:563-569.
• [35]Wei K, Wang Y, Liang Z: An analysis of incidence with cervical cancer in 1970 ~ 2007 in Zhongshan city, Guangdong province. China Cancer 2012, 21:495-497. in Chinese
• [36]Sharma M, Bruni L, Diaz M, Castellsagué X, de Sanjosé S, Bosch FX, Kim JJ: Using HPV prevalence to predict cervical cancer incidence. Int J Cancer 2013, 132:1895-1900.
• [37]Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, Ning L, Killeen J, Kamemoto L, Hernandez BY: Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii human papillomavirus cohort study. Cancer Res 2008, 68:8813-8824.
• [38]Gravitt PE, Rositch AF, Silver MI, Marks MA, Chang K, Burke AE, Viscidi RP: A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2012, 207:272-280.
• [39]Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N: Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl 1):K1-K16.
• [40]Strickler HD, Kirk GD, Figueroa JP, Ward E, Braithwaite AR, Escoffery C, Drummond J, Goebel B, Waters D, McClimens R, et al.: HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer 1999, 80:339-344.
• [41]González P, Hildesheim A, Rodríguez AC, Schiffman M, Porras C, Wacholder S, Piñeres AG, Pinto LA, Burk RD, Herrero R: Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev 2010, 19:3044-3054.
• [42]Lai CH, Chao A, Chang CJ, Chao FY, Huang HJ, Hsueh S, Lin CT, Cheng HH, Huang CC, Yang JE, et al.: Host and viral factors in relation to clearance of human papillomavirus infection: a cohort study in Taiwan. Int J Cancer 2008, 123:1685-1692.
• [43]Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A, et al.: Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003, 168:421-425.
• [44]de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
• [45]The Lancet: Women’s health in rural China Lancet 2009, 374:358.
• [46]Méndez F, Muñoz N, Posso H, Molano M, Moreno V, van den Brule AJ, Ronderos M, Meijer C, Muñoz A, et al.: Cervical coinfection with Human Papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005, 192:1158-1165.
• [47]Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco EL, Poole C, Smith JS: Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer 2013, 133:1271-1285.
• [48]Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R: Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008, 100:513-517.
• [49]Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, Morales J, Guillen D, Sherman ME, Solomon D, et al.: Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009, 339:b2569.